Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment

Brain Research

Volumn 993, Issue 1-2, 2003, Pages 1-9

  Campbell, Brian M ^a   Merchant, Kalpana M ^a  

^a PFIZER INC   (United States)

Author keywords

Basolateral amygdala; Fear; Serotonin 2

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; IL 639; PROTEIN C FOS; SEROTONIN 2 AGONIST; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR;

AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; BASOLATERAL MEMBRANE; BEHAVIOR; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SPECIFICITY; FEAR; MALE; NERVE CELL; NONHUMAN; ONCOGENE C FOS; OPEN FIELD BEHAVIOR; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0345714770     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)03384-5     Document Type: Article

References (39)

1. Acuna-Castillo C., Scorza C., Reyes-Parada M., Cassels B.K., Huidobro-Toro J.P. ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropanolamine derivative, is a 5-HT2A and 5-HT2C agonist. Life Sci. 67:2000;3241-3247.
2. Bagdy G., Graf M., Anheuer Z.E., Modos E.A., Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int. J. Neuropsychopharmacol. 4:2001;399-408.
3. Bilkei-Gorzo A., Gyertyan I., Levay G. mCPP-induced anxiety in the light-dark box in rats - a new method for screening anxiolytic activity. Psychopharmacology. 136:1998;291-298.
4. Chaouloff F. Serotonin, stress and corticoids. J. Psychopharmacol. 14:2000;139-151.
5. Charney D.S., Woods S.W., Goodman W.K., Heringer G.R. Serotonin function in anxiety: II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psychopharmacology. 92:1987;14-24.
6. Curran T., Gordon M.B., Rubino K.L., Sambucceti L.C. Isolation and characterization of the c-fos(rat) cDNA and analysis of post-translational modification in vitro. Oncogene. 2:1987;79-84.
7. Davidson R.J., Abercrombie H., Nitschke J.B., Putnam K. Regional brain function, emotion and disorders of emotion. Curr. Opin. Neurobiol. 9:1999;28-234.
8. Davis M., Cassella J.V., Wrean W.H., Kehne J.H. Serotonin receptor subtype agonists: differential reactivity measured with acoustic startle. Psychopharmacol. Bull. 22:1986;837-843.
9. Drevets W.C. Neuroimaging studies of mood disorders. Biol. Psychiatry. 48:2002;813-829.
10. Erzegovesi S., Martucci L., Henin M., Bellodi L. Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology. 24:2001;31-36.
11. Fiorella D., Helsley S., Rabin R.A., Winter J.C. 5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology. 122:1995;237-243.
12. Gleason S.D., Shannon H.E. Meta-chlorophenylpiperazine induced changes in locomotor activity are mediated by 5-HT1 as well as 5-HT2C receptors in mice. Eur. J. Pharmacol. 341:1998;135-138.
13. Gonzalez L.E., Andrews N., File S.E. 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res. 732:1996;145-153.
14. Graeff F.G., Guimaraes F.S., De Andrade T.G.C.S., Deakin J.F. Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 54:1996;129-141.
15. Graeff F.G., Viana M.B., Mora P.O. Dual role of 5-HT in defense and anxiety. Neurosci. Biobehav. Rev. 21:1997;791-799.
16. Heisler L.K., Tecott L.H. A paradoxical locomotor response in serotonin 5-HT2C receptor mutant mice. J. Neurosci. 20(1-5):2000;RC71.
17. Hodges H., Green S., Glenn B. Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not on discrimination. Psychopharmacology. 92:1987;491-504.
18. Huidobro-Toro J.P., Valenzuela C.F., Harris R.A. Modulation of GABAA receptor function by G protein-coupled 5-HT2C receptors. Neuropsychopharmacology. 35:1996;1355-1363.
19. Jelen P., Soltysik S., Zagrodzka J. 22-kHz ultrasonic vocalization in rats as an index of anxiety but not fear: behavioral and pharmacological modulation of affective state. Behav. Brain Res. 141:2003;63-72.
20. Kawahara H., Yoshida M., Yokoo H., Nishi M., Tanaka M. Psychological stress increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci. Lett. 162:1993;81-84.
21. Kennett G.A., Whitton P., Shah K., Curzon G. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur. J. Pharmacol. 164:1989;445-454.
22. 2C receptor antagonist. Neuropharmacology. 36:1997;609-620.
23. Mengod G., Nguyen H., Le H., Waeber C., Lubbert H., Palacios J.M. The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience. 35:1990;577-591.
24. Montgomery K.C. The relation between fear induced by novelty stimulation and exploratory behavior. J. Comp. Physiol. Psychol. 48:1955;254-260.
25. Mora P.O., Netta C.F., Graeff F.G. Role of 5-HT2A and 5-HT2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol. Biochem. Behav. 58:1997;1051-1057.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
27. Pompeiano M., Palacios J.M., Mengod G. Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Mol. Brain Res. 23:1994;163-178.
28. Rainnie D.G. Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J. Neurophysiol. 82:1999;69-85.
29. Robichaud A.J., Chen W., McClung C., Stranz M., Clark D., Deng W., Calvello E.B., Mitchell I.S., Lee T., Rajagopalan P., Robertson D.W., Molino B.F., Haydar S.N., Conlon M.P., Duffy B.C., Liao J., Pawlush N.G., Fitzgerald L.W., Conklin D.S., Krause C.M., McElroy J.F., Rohrbach K.W., Miller K.J., Largent B.L. Synthesis and biological evaluation of novel, selective 5-HT2C receptor agonists for the treatment of obesity. 221st Amer. Chem. Soc. Abst. 2001.
30. Rodgers R.J. Animal models of 'anxiety': where next? Behav. Pharmacol. 8:1997;477-496.
31. Roth B.L., Kroeze W.K., Patel S., Lopez E. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? The Neuroscientist. 6:2000;252-262.
32. Russell P.A. Relationship between exploratory behaviour and fear: a review. Br. J. Psychol. 64:1973;417-433.
33. Sanchez C. Stess-induced vocalization in adult animals. A valid model of anxiety? Eur. J. Pharmacol. 463:2003;133-143.
34. Scorza M.C., Reyes-Parada M., Silveira R., Viola H., Medina J.H., Viana M.B., Zangrossi H. Jr., Graeff F.G. Behavioral effects of the putative anxiolytic (±)-1-(2,5-dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2) in rats and mice. Pharmacol. Biochem. Behav. 54:1996;355-361.
35. Shah A.A., Treit D. Excitotoxic lesions of the medial prefrontal cortex attenuate fear responses in the elevated-plus maze, social interaction and shock probe burying tests. Brain Res. 969:2003;183-194.
36. Stein D.J., Stahl S. Serotonin and anxiety: current models. Int. Clin. Psychopharmacol. 15(Suppl. 2):2000;S1-S6.
37. Stein C., Davidowa A., Albrecht D. 5-HT(1A) receptor-mediated inhibition and 5-HT(2) as well as 5-HT(3) receptor-mediated excitation in different subdivisions of the rat amygdala. Synapse. 38:2000;328-337.
38. Stutzmann G.E., LeDoux J.E. GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J. Neurosci. 19:1999;RC8.
39. Zangrossi H. Jr., Viana M.B., Graeff F.G. Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino)tetr alin in the elevated T-maze. Eur. J. Pharmacol. 369:1999;267-270.